Literature DB >> 7934443

Direct estimates of cancer mortality due to low doses of ionising radiation: an international study. IARC Study Group on Cancer Risk among Nuclear Industry Workers.

.   

Abstract

When setting standards for protection against ionising radiation it has been usual to extrapolate from experience with high-dose short-term exposure--studies based on atom bomb survivors and patients exposed to radiation therapeutically. Those who work in the nuclear industry are exposed to low-level predominantly gamma radiation for longer periods, and provide an alternative direct source of information. We have combined mortality data from seven cohort studies on nearly 96,000 nuclear industry workers monitored for external radiation in Canada, UK, and USA to assess directly the carcinogenic effects of protracted low-dose exposure to ionising radiation. The excess relative risk for death from leukaemia, excluding chronic lymphocytic leukaemia, was 2.2 per Sv (90% Cl 0.1 to 5.7). This estimate is intermediate between the linear estimate of 3.7 per Sv and the linear-quadratic estimate (as used in recent leukaemia risk assessments) of 1.4 per Sv derived from Japanese atomic bomb survivors' data. The excess relative risk for death from all cancers, excluding leukaemia, was -0.07 per Sv (90% Cl -0.4 to 0.3). This estimate is consistent with a range of risks varying from negative to nearly twice those estimated from atomic bomb survivors (0.18 per Sv). These are the most precise direct estimates so far made of carcinogenic risk after protracted exposure to low-dose ionising radiation. They provide little evidence that the estimates that form the basis of current radiation protection recommendations are appreciably in error.

Entities:  

Mesh:

Year:  1994        PMID: 7934443

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

1.  Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries.

Authors:  E Cardis; M Vrijheid; M Blettner; E Gilbert; M Hakama; C Hill; G Howe; J Kaldor; C R Muirhead; M Schubauer-Berigan; T Yoshimura; F Bermann; G Cowper; J Fix; C Hacker; B Heinmiller; M Marshall; I Thierry-Chef; D Utterback; Y-O Ahn; E Amoros; P Ashmore; A Auvinen; J-M Bae; J Bernar Solano; A Biau; E Combalot; P Deboodt; A Diez Sacristan; M Eklof; H Engels; G Engholm; G Gulis; R Habib; K Holan; H Hyvonen; A Kerekes; J Kurtinaitis; H Malker; M Martuzzi; A Mastauskas; A Monnet; M Moser; M S Pearce; D B Richardson; F Rodriguez-Artalejo; A Rogel; H Tardy; M Telle-Lamberton; I Turai; M Usel; K Veress
Journal:  BMJ       Date:  2005-06-29

2.  Cancer mortality risk among military participants of a 1958 atmospheric nuclear weapons test.

Authors:  K K Watanabe; H K Kang; N A Dalager
Journal:  Am J Public Health       Date:  1995-04       Impact factor: 9.308

3.  Induction of apoptosis in human leukemia cells by grape seed extract occurs via activation of c-Jun NH2-terminal kinase.

Authors:  Ning Gao; Amit Budhraja; Senping Cheng; Hua Yao; Zhuo Zhang; Xianglin Shi
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

Review 4.  Getting ready for the manned mission to Mars: the astronauts' risk from space radiation.

Authors:  Christine E Hellweg; Christa Baumstark-Khan
Journal:  Naturwissenschaften       Date:  2007-01-19

5.  Radiation and mortality of workers at Oak Ridge National Laboratory: positive associations for doses received at older ages.

Authors:  D B Richardson; S Wing
Journal:  Environ Health Perspect       Date:  1999-08       Impact factor: 9.031

6.  Risk of cancer from occupational exposure to ionising radiation: retrospective cohort study of workers in France, the United Kingdom, and the United States (INWORKS).

Authors:  David B Richardson; Elisabeth Cardis; Robert D Daniels; Michael Gillies; Jacqueline A O'Hagan; Ghassan B Hamra; Richard Haylock; Dominique Laurier; Klervi Leuraud; Monika Moissonnier; Mary K Schubauer-Berigan; Isabelle Thierry-Chef; Ausrele Kesminiene
Journal:  BMJ       Date:  2015-10-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.